Tech Company Financing Transactions
Revolution Medicines Funding Round
On 4/25/2018, Revolution Medicines announced $56 million in Series B funding from Nextech Invest, Casdin Capital and Schroder Adveq.
Transaction Overview
Company Name
Announced On
4/25/2018
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series B
Investors
Nextech Invest (Lead Investor) (Thilo Schroeder)
The Column Group (Larry Lasky)
Proceeds Purpose
The raise of new capital, expansion of our executive team and board with seasoned leaders, and multiple presentations about progress in our SHP2 program at the recent AACR conference all reflect enormous momentum in our effort to outsmart cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Revolution Medicines (Nasdaq: RVMD) discovers and develops important new medicines for cancer patients by translating frontier oncology targets--proteins that drive the growth of cancers or that control immune responses that can defeat them.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Goldsmith
Chief Operating Officer
Margaret Horn
Vice President
Adrian Gill
Vice President
Richard Hansen
Vice President
Walter Reiher
Vice President
Jan Smith
Vice President
Xiaolin Wang
VP - Finance
Jack Anders
VP - Human Resources
Luan Wilfong
VP - R & D
Steve Kelsey
Browse more venture capital transactions:
Prev: 4/25/2018: MobileCoin venture capital transaction
Next: 4/25/2018: Brud venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs